PTGX FY 2022 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$27M-2.8% YoY

Gross Profit

$27M100.0% margin

Operating Income

-$131M-494.2% margin

Net Income

-$127M-479.3% margin

EPS (Diluted)

$-2.52

Cash Flow

Operating Cash Flow

-$108M

Free Cash Flow

-$109M

Stock-Based Comp.

$24M

Balance Sheet

Total Assets

$248M

Total Liabilities

$32M

Stockholders' Equity

$216M

Cash & Equivalents

$126M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$27M	$27M	-2.8%
Gross Profit	$27M	$27M	-2.8%
Operating Income	-$131M	-$126M	-4.4%
Net Income	-$127M	-$126M	-1.5%